Jennison Associates
EW icon

Jennison Associates’s Edwards Lifesciences EW Stock Holding History

Jennison Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,800,000
Closed -$20.2M – 698
2013
Q2 		$20.2M Buy
+1,800,000
New +$21.3M 0.02% 430

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Jennison Associates's EW Position: Q1 2026 in Review

Jennison Associates reduced its Edwards Lifesciences (EW) stake by 5.2% in Q1 2026, selling an estimated $58.9M and leaving 13,066,274 shares worth $1.05B. The position accounts for 0.72% of the portfolio, ranked #32.

Jennison Associates first reported a position in EW in Q2 2015 and has held it in 26 quarters since. The position peaked at $1.34B in Q3 2019. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Jennison Associates held 13,066,274 shares of Edwards Lifesciences worth $1.05B as of Q1 2026.
  • Jennison Associates sold 714,241 Edwards Lifesciences shares in Q1 2026, an estimated $58.9M.
  • Edwards Lifesciences made up 0.72% of Jennison Associates's portfolio in Q1 2026, its #32 holding.
  • Jennison Associates first reported a position in Edwards Lifesciences in Q2 2015 and has held it in 26 quarters since.
  • Jennison Associates's Edwards Lifesciences position peaked at $1.34B in Q3 2019.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.